SecBot SecBot
6-K ·Filed Oct 27, 2026

IPHA

Innate Pharma SA
NEUTRAL
Impact 4/10
Processed4h 48m ago SEC0001628280-26-067408
Notable filing: 6-K

Price Chart

Loading chart...

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-067408
Document: a6kincorporatediph_261027.htm0001628280-26-067408
Document: 0001628280-26-067408-index-headers.html0001628280-26-067408
Document: 0001628280-26-067408-index.html0001628280-26-067408
Document: 0001628280-26-067408.txt0001628280-26-067408
13 reports for IPHA
Performance horizon
0% Hit rate @ T+20 0 of 3 directional calls Went positive at some point 0 of 3 best @ T+1▼ −0.52%Sep 16, 2026
Filters
Rows
Reports for IPHA — sortable, filterable
TypeNow
Oct 27, 2026
today
6-K
NEUTRAL ★ 4/10
$1.54awaiting T+20—$1.47 (−4.71%)
Oct 21, 2026
6d ago
6-K
NEUTRAL ★ 2/10
$1.57awaiting T+20—$1.47 (−6.53%)
Oct 20, 2026
7d ago
6-K
NEUTRAL ★ 2/10
$1.58awaiting T+20—$1.47 (−7.00%)
Sep 17, 2026
5w ago
6-K
BULLISH ★ 7/10
$1.91 $1.48▼ −22.51%▼ −23.97%$1.47 (−23.17%)
Sep 17, 2026
5w ago
6-K
MIXED ★ 6/10
$1.91 $1.48▼ −22.51%▼ −23.97%$1.47 (−23.17%)
Sep 17, 2026
5w ago
6-K
BULLISH ★ 7/10
$1.91 $1.48▼ −22.51%▼ −23.97%$1.47 (−23.17%)
Sep 16, 2026
5w ago
Press Release
BULLISH ★ 6/10
$1.91 $1.48▼ −22.51%▼ −23.97%$1.47 (−23.17%)
Sep 10, 2026
6w ago
6-K
NEUTRAL ★ 3/10
$1.88 $1.48▼ −21.28%▼ −23.40%$1.47 (−21.94%)
Sep 2, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$2.17 $1.63▼ −24.88%▼ −24.80%$1.47 (−32.37%)
Aug 14, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$2.18 $1.85▼ −15.14%▼ −13.15%$1.47 (−32.68%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 27, 2026

Fresh IPHA Intelligence

Analysis is for subscribers only.

Subscribe for Full Access